文献速递角膜与眼表疾病神经眼科

米罗加巴林对泪液缺乏型干眼大鼠痛觉过敏及慢性眼痛的影响

Effects of Mirogabalin on Hyperalgesia and Chronic Ocular Pain in Tear-Deficient Dry-Eye Rats.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

研究在切除眶外泪腺和哈德氏腺的雌性Sprague Dawley大鼠干眼模型中,评估米罗加巴林对痛觉过敏和慢性眼痛的作用。结果显示去腺后4周出现痛觉过敏和慢性眼痛,米罗加巴林5天给药显著抑制辣椒素诱导的甩眼行为,10 mg/kg显著减少三叉神经核c-Fos表达。作者认为米罗加巴林可能有效缓解干眼患者的慢性眼痛。

要点

  • 去眶外泪腺和哈德氏腺后4周,大鼠出现角膜痛觉过敏和慢性眼痛。
  • 米罗加巴林5天给药显著抑制辣椒素诱导的甩眼行为,提示抑制眼痛觉过敏。
  • 10 mg/kg米罗加巴林显著减少三叉神经核c-Fos表达,提示改善慢性眼痛。

核心结论

  • 米罗加巴林在干眼大鼠模型中抑制了干眼诱导的痛觉过敏和慢性眼痛。
  • 作者认为米罗加巴林可能有效缓解干眼患者的慢性眼痛。

研究设计与样本

  • 研究为动物实验,在雌性Sprague Dawley大鼠中单侧切除眶外泪腺和哈德氏腺诱导干眼。
  • 去腺后4周评估泪液分泌(pH试纸)和角膜上皮损伤(荧光素染色),并分别通过辣椒素诱导甩眼行为和三叉神经核c-Fos表达分析角膜痛觉过敏和慢性眼痛。
  • 评估米罗加巴林10或3 mg/kg对干眼诱导痛觉过敏和慢性眼痛的作用。

主要发现

  • 干眼诱导眼泪液分泌显著低于对照眼。
  • 干眼眼角膜损伤显著高于对照眼。
  • 去眶外泪腺和哈德氏腺后4周检测到痛觉过敏和慢性眼痛。
  • 米罗加巴林给药5天显著抑制辣椒素诱导的甩眼行为,提示抑制眼痛觉过敏。
  • 10 mg/kg米罗加巴林显著减少三叉神经核c-Fos表达,提示改善慢性眼痛。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with dry eye disease (DED) sometimes complain of ocular pain. DED-related ocular pain has many similarities with neuropathic pain. Mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels, is approved for treating neuropathic pain in Japan. This study aimed to investigate the effect of mirogabalin on hyperalgesia and chronic ocular pain in a rat DED model. METHODS: DED was induced in female Sprague Dawley rats by unilaterally excising the external lacrimal gland (ELG) and Harderian gland (HG). After 4 weeks of ELG and HG removal, tear production (pH threads) and corneal epithelial damage (fluorescein staining) were evaluated. Corneal hyperalgesia and chronic pain were analyzed, respectively, by measuring capsaicin-induced eye-wiping behavior and c-Fos expression in the trigeminal nucleus. Mirogabalin (10 or 3 mg/kg) was evaluated for effects on DED-induced hyperalgesia and chronic ocular pain. RESULTS: Tear production was significantly lower in DED-induced eyes than in control eyes. Corneal damage was significantly higher in DED eyes than in control eyes. Hyperalgesia and chronic ocular pain were detected 4 weeks after ELG and HG removal. Five days of mirogabalin administration significantly suppressed capsaicin-induced eye-wiping behavior, which indicated the suppression of ocular hyperalgesia. Administration of 10 mg/kg mirogabalin significantly reduced c-Fos expression in the trigeminal nucleus, which indicated the amelioration of chronic ocular pain. CONCLUSIONS: Mirogabalin suppressed DED-induced hyperalgesia and chronic ocular pain in a rat DED model. Our findings suggested that mirogabalin might effectively alleviate chronic ocular pain in patients with DED.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Kikuchi K, Tagawa Y, Murata M, et al. Effects of Mirogabalin on Hyperalgesia and Chronic Ocular Pain in Tear-Deficient Dry-Eye Rats. Invest Ophthalmol Vis Sci. 2023. PMID: 37233999. doi:10.1167/iovs.64.5.27

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。